Ozempic vs Wegovy vs Mounjaro: And The Effects on How You Look
- 1 day ago
- 8 min read
Ozempic, Wegovy and Mounjaro have gone from clinical names recognised mainly by diabetes specialists to some of the most searched medications in the UK. If you are weighing up whether one of these treatments is right for you, or you have already started one and you are noticing changes in your face, skin or hair, this guide covers what these medications are, who can access them, what current research actually shows, and what they do to your appearance along the way.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. GLP-1 medications are prescription-only in the UK. Always consult a qualified prescriber before starting, changing or stopping any medication.
What Is Ozempic?
Ozempic is the brand name for semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist manufactured by Novo Nordisk. It is given as a weekly injection.
Your gut naturally produces GLP-1 after you eat. It tells your brain you are full, slows down digestion, and triggers the release of insulin. Semaglutide mimics this hormone at levels far higher than your body produces on its own, which is why it reduces appetite, slows stomach emptying and improves blood sugar control.
In the UK, semaglutide is licensed under two different brand names depending on what it is being used for: Ozempic for type 2 diabetes, and Wegovy for weight management. Ozempic itself is not licensed for weight loss in the UK. Reputable private prescribers will not give it to you for that purpose; they will offer Wegovy instead, which contains the same active ingredient at a higher dose.
The GLP-1 Family: Ozempic, Wegovy, Mounjaro and More
Most people only know the name Ozempic, but it is one of several branded medications built on two active ingredients: semaglutide and tirzepatide. Here is how the main UK options break down.
Ozempic (semaglutide, Novo Nordisk): licensed in the UK for type 2 diabetes only. Maximum dose 2mg per week.
Wegovy (semaglutide, Novo Nordisk): licensed for weight management. Maximum dose now 7.2mg per week, following MHRA approval of a higher dose in January 2026.
Rybelsus (semaglutide, Novo Nordisk): a daily oral tablet version, licensed for type 2 diabetes.
Mounjaro (tirzepatide, Eli Lilly): a dual GLP-1 and GIP receptor agonist, acting on two appetite hormones instead of one. Licensed for both type 2 diabetes and weight management, maximum dose 15mg per week. Trial data generally shows stronger weight loss than semaglutide alone.
Saxenda (liraglutide, Novo Nordisk): an older daily injectable GLP-1 medication licensed for weight management, now less commonly prescribed than the weekly options.
Who Can Take These Medications in the UK?
Access depends entirely on what the medication is licensed for and which route you take, NHS or private.
Ozempic on the NHS
You can only get Ozempic on the NHS if you have type 2 diabetes that is not well controlled by diet, exercise and other diabetes medications. Over 4 million people in the UK live with type 2 diabetes, but only some meet the specific NICE criteria for an Ozempic prescription.
Wegovy and Weight Management
Wegovy was approved by NICE for weight management in 2023, but NHS access remains limited. It is currently only available through select NHS weight management services, usually requiring a BMI above a set threshold alongside participation in a structured programme. For most people seeking weight loss support, this route is not yet widely accessible.
Private Prescriptions
Private prescriptions are the most common route for weight management. Private Wegovy typically costs £200 to £300 a month, while private Ozempic prescriptions for diabetes run £150 to £250 a month. These prices usually include the consultation, prescription charge and medication supply.
Who Should Not Take Them
These medications are not suitable for everyone. They are generally avoided in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Type 2, during pregnancy, and in people with certain gastrointestinal conditions. It is also worth knowing that the MHRA warned in 2025 that weight loss drugs could reduce the effectiveness of oral contraception, so anyone relying on the pill should discuss backup contraception with their prescriber.
What Does the Research Actually Show?
The evidence for GLP-1 medications has expanded well beyond weight loss and diabetes control. It is worth separating what is well established from what is still emerging.
Established Benefits
Weight loss: up to 15 to 17 percent of body weight with Wegovy in trials, with newer high-dose data showing even greater results. Tirzepatide (Mounjaro) trials have shown over 20 percent in some patients.
Type 2 diabetes management: improved blood sugar control, the medication's original approval purpose.
Cardiovascular risk reduction: large trials have shown semaglutide reduces major heart events, including heart-related death, in people with both obesity and existing heart disease.
Kidney protection: in January 2025, the FDA approved semaglutide (as Ozempic) specifically to lower the risk of worsening kidney disease and kidney failure in adults with type 2 diabetes and chronic kidney disease, the first GLP-1 medication approved for this use. Trial data showed a 24 percent reduction in major kidney disease events.
Liver disease: a major clinical trial found semaglutide can halt, and in some cases reverse, a common liver condition called MASH after 72 weeks of treatment.
Emerging Research (Early Stage, Worth Watching)
These findings come from smaller or more recent studies and should be treated as promising rather than proven.
Biological aging: a randomised, placebo-controlled trial from UC San Diego found semaglutide slowed biological aging across multiple epigenetic markers.
Neurological effects: preliminary research published in the journal Neurology found people with type 2 diabetes using semaglutide had a lower association with epilepsy risk compared with other diabetes medications.
Addiction and sleep: early studies suggest a possible reduction in alcohol use and smoking, while tirzepatide has shown significant improvement in sleep apnoea severity in dedicated trials.
Side Effects: What to Expect
Common Side Effects
More than 1 in 10 users experience nausea and diarrhoea, particularly when starting the medication or increasing the dose. These often settle over time. Vomiting, constipation, stomach discomfort, reduced appetite, acid reflux and fatigue are also common.
Serious But Less Common
Acute pancreatitis: sudden, severe stomach or back pain needs immediate medical attention.
Gallbladder problems, including gallstones.
Kidney issues, usually linked to dehydration from vomiting or diarrhoea.
Thyroid concerns: a systematic review of 10 randomised controlled trials involving over 14,500 participants found thyroid cancer incidence in semaglutide users was under 1 percent, suggesting no significant added risk.
Weight regain: stopping the medication often leads to significant weight regain, confirmed by a large analysis of 11 global studies.
The Aesthetic Side Effects
This is the part most explainer articles skip, and it is where Doctors see patients most often.
“Ozempic face” and “Wegovy face” describe the facial changes that can appear during significant weight loss on GLP-1 medicines. These are not a direct drug side effect; they are a visible result of fat loss, sometimes combined with temporary dehydration and reduced skin elasticity. Most patients notice a more hollow mid-face, especially around the cheeks and temples. If you are exploring how to address this, our guide to facial volume restoration covers the non-surgical options available.
You are more likely to notice these changes if your total weight loss is more than 10 to 15 percent of your body weight, if the weight comes off quickly, if you naturally carry less facial fat, if you are over 35, or if you have a history of sun exposure or smoking, all of which reduce skin elasticity over time.
Hair shedding is another common consequence of rapid weight loss. Telogen effluvium, a temporary, diffuse hair thinning, is a known physiological response to significant caloric deficit and nutritional stress, not a direct drug side effect. We cover the causes and treatment options in more depth in why your hair stops growing.
Muscle loss is a genuine and growing concern in the research community. An ongoing observational study, the GLIMMER trial, is using MRI scans to track changes in both muscle and fat over 12 months in people starting semaglutide, reflecting real concern about preserving muscle health during rapid weight loss, particularly for people already at higher risk.
Skin laxity following significant weight loss is closely related to facial volume loss, just affecting the body rather than the face. Our guide to skin boosters breaks down the non-surgical options for restoring skin quality.
Frequently Asked Questions
Is Ozempic the same as Wegovy?
They contain the same active ingredient, semaglutide, but they are licensed for different purposes and given at different doses. Ozempic is licensed for type 2 diabetes up to 2mg per week. Wegovy is licensed for weight management up to 7.2mg per week.
Can I get Ozempic on the NHS for weight loss?
No. Ozempic is only available on the NHS for type 2 diabetes that meets specific NICE criteria. If you want a semaglutide injection for weight management, the licensed NHS and private route is Wegovy.
How much weight can I expect to lose?
Trial data shows Wegovy users lose an average of 15 to 17 percent of body weight, with the newer 7.2mg dose reaching over 20 percent in some studies. Mounjaro trials have shown even higher results for some patients. Individual results vary significantly.
What is “Ozempic face”?
It is an informal term for facial hollowing, particularly in the cheeks and temples, that can appear during significant weight loss on GLP-1 medications. It is a result of fat and volume loss, not a direct side effect of the drug itself.
Will my face go back to normal if I stop taking it?
Not always. If you have lost significant facial fat and your skin has lost elasticity, the face may not return to its previous appearance on its own. Many patients use targeted dermal filler or skin treatments to restore structure.
Does Ozempic cause hair loss?
Hair shedding linked to GLP-1 medications is usually telogen effluvium, a temporary thinning triggered by rapid weight loss and nutritional stress rather than the medication itself. It is typically reversible once weight stabilises and nutrition improves.
Is Mounjaro better than Ozempic or Wegovy?
Mounjaro (tirzepatide) targets two appetite hormones instead of one and has shown stronger average weight loss results in trials compared with semaglutide. It is licensed in the UK for both diabetes and weight management.
What are the most common side effects?
Nausea and diarrhoea affect more than 1 in 10 users, especially when starting treatment or increasing the dose. These usually improve over time as your body adjusts.
How much does private treatment cost in the UK?
Private Wegovy typically costs £200 to £300 a month. Private Ozempic prescriptions for diabetes cost £150 to £250 a month. Prices usually include consultation and monitoring.
Can I take Ozempic if I am not diabetic?
Ozempic itself is licensed only for type 2 diabetes in the UK, so reputable prescribers will not give it to non-diabetic patients for weight loss. Wegovy, which contains the same active ingredient at a higher dose, is the licensed option for weight management.
What Comes Next
Understanding the medication is only half the picture. If you are already on a GLP-1 medication, or considering one, the more useful question is often what happens to your face, skin and body during and after significant weight loss, and what can actually be done about it. We will cover that in detail in our companion guide on treating the aesthetic effects of GLP-1 weight loss.
If you are noticing facial hollowing, skin laxity or hair changes during your weight loss journey, our team at Beauthic Talk can assess what is happening and talk through the non-surgical options available to you.
Read more on NHS website.
Comments